Hennion & Walsh Asset Management, Inc. Neurocrine Biosciences Inc Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 6,161 shares of NBIX stock, worth $847,260. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,161
Previous 6,307
2.31%
Holding current value
$847,260
Previous $697,000
11.05%
% of portfolio
0.03%
Previous 0.03%
Shares
13 transactions
Others Institutions Holding NBIX
# of Institutions
660Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.95 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.35 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$766 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$614 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$424 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...